NRx Pharmaceuticals, Inc.
NRXP
$-0.02
Change (1 day)
$7.33
Year High
$1.10
Year Low
Categories
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals, Inc. (NRXP) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 6 K | 4.57 M | 19.05 M | 7.32 M | 6.88 M |
| 2022 | -9,529,000 | 18.41 M | 25.82 M | 25.8 M | |
| 2021 | -27,087,000 | 11.92 M | 32.73 M | 32.71 M | |
| 2020 | 831 K | -1,062,000 | 46.71 M | 2.94 M | 2.93 M |
| 2019 | 1.95 M | 2.57 M | 32.07 M | 69.49 K |